Rallybio Corp

NASDAQ RLYB

Data sourced from

and

Download Data

Rallybio Corp Working Capital to Current Liabilities Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -39.14%

Rallybio Corp Working Capital to Current Liabilities Ratio 2 year CAGR is -39.14% for the Trailing 12 Months (TTM) ending March 31, 2024, a -291.65% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Rallybio Corp Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 17.56, a -25.85% change year over year.
Rallybio Corp Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 23.68, a 9.25% change year over year.
Rallybio Corp Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 21.67.

NASDAQ: RLYB

Rallybio Corp

CEO	Dr. Martin W. MacKay Ph.D.
IPO Date	July 29, 2021
Location	United States
Headquarters	234 Church Street, New Haven, CT, United States, 06510
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Key trends